It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Incorporating alternative investments into your long-term portfolio can enhance diversification and improve returns.
27,567 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
When sandisk stock just popped, traders watched for AI data-center demand and memory-market signals. This article bre...
Robinhood launched a new layer-2 blockchain to tokenized real-world assets, yet the initial trading frenzy centered o...
Altria just posted strongest growth in years, signaling a potential turning point. But behind the headlines lie shift...
Oklo has shed 28% over the past month as investors rotate away from pre-revenue nuclear developers. Utilities remain ...
Oracle's backlog surge and accelerating AI infrastructure growth are fueling a heated debate on whether the stock is ...
SpaceX priced its IPO at a fixed $135 per share, aiming to raise roughly $75 billion and valuing the company around $...
Target’s stock has surged 33% from October lows, prompting renewed questions about a possible buyout. This report ana...
Tech stocks lead market declines as traders weigh higher-for-longer rates against cooling AI chip enthusiasm and a su...
LINK jumped about 14% in 24 hours, reclaiming the $9 range on renewed interest in Canton Network integration and gro...
Three Dow components lag this year, sharing three pressure points that investors still see as catalysts. Wall Street ...
Russia’s accusation that the United States carried out a ‘pre-planned’ strike against Iran jolts global markets as oi...